Importers race to turn U.S. warehouses into tariff-free zones
A container ship sails off from a container terminal in Qingdao in eastern China's Shandong province Sunday, April 6, 2025. (Chinatopix Via AP)
LONDON/NEW YORK - Companies importing goods into the United States from China are rushing to convert warehouses into facilities that are exempt from President Donald Trump's tariffs until they are ready to sell the merchandise.
The U.S. has more than 1,700 bonded warehouses, facilities where imported goods can be held without immediate payment of customs duties such as tariffs, currently 30% for shipments from China. Such fees are only paid when the goods leave the bonded warehouse, allowing businesses to manage funds more effectively at a time of extreme trade policy volatility.
The rush to bond U.S. warehouses for goods ranging from clothing to auto parts is a bet for some that raised U.S. tariffs will be only a short-term policy by the Trump administration.
Due to Trump's tariff war, many of these bonded warehouses are now at full capacity, and prices for space in them have skyrocketed, four industry sources told Reuters, prompting companies to apply to U.S. Customs and Border Protection to expand bonded space.
Utah-based fulfillment firm LVK Logistics, for instance, is in the process of making one of its warehouses bonded 'in response to the tariffs,' CEO Maggie Barnett told Reuters, adding she expects the process to take three to four months.
'You can bond more or less anywhere,' said Chris Rogers, who manages the supply chain research team at consultancy S&P Global Market Intelligence. 'It involves money and it takes time, but if you are a big company and expect tariffs are going to remain elevated for an extended period, you can convert (existing) spaces into bonded warehousing.'
Other companies and logistics firms are seeing their applications with the CBP backlogged in some cases by over six months, said Chris Huwaldt, vice president of solutions at WarehouseQuote, a logistics research firm. Last year, the process would have taken a couple of months, he added.
Huwaldt said getting storage space certified as bonded 'could cost thousands of dollars or it could cost six figures,' depending on the state the warehouse is based in, the financial status of the company and the additional security measures required by the CBP for a specific location.
Trump's on-again, off-again tariff policy - which pushed duties on Chinese goods to as much as 145 per cent in April before lowering them - makes the flexibility afforded by bonded warehouses appealing to companies.
'A lot of companies importing from China - not just China-based, but U.S. importers as well - are taking advantage of bonded warehouses to assist with cash flow,' said Cindy Allen, shipping consultant at Trade Force Multiplier and a former FedEx Logistics executive.
'It doesn't necessarily save them money as the tariffs have to be paid when the goods are withdrawn from the warehouse. But it allows companies to pay duties in smaller increments as they are sold,' she said.
The CBP said it has noticed an increased interest in the use of bonded warehouses for continued compliance with new regulations and executive orders.
The White House did not immediately respond to a request for comment.
'Unprecedented' warehouse rush
In early 2024, bonded storage space was rented at approximately twice the cost of standard storage rates, but since the start of 2025, it has risen to four times the price to rent non-bonded space, according to WarehouseQuote data.
'This rush to bonded warehouses to ease cash flow is unprecedented,' Allen said.
During the first Trump administration, many companies simply accepted the levies on China. But this meant firms paid more over a prolonged period of time while also being forced to invest in alternative sources to China. Importers 'don't want to repeat the past mistakes,' Allen said.
Setting up new bonded warehouses could be risky, because the United States may go back to higher tariffs once its 90-day reprieve ends.
Vladimir Durshpek, cofounder of Venice, Florida-based warehousing and storage company CargoNest, said he is weighing adding a third bonded warehouse to his assets until U.S. tariff negotiations are completed.
'What we don't want to do is rush into providing more capacity, and then things change,' he said.
Fremont, California-based storage company DCL Logistics has not made definitive plans for bonded space because 'it's unclear if the demand will stay this high,' Chief Revenue Officer Brian Tu said.
'By the time a lot of warehouses would be able to achieve bonded status right now, these additional tariffs might be gone, and the demand for bonded space might not be there,' said Jacob Roseburrough, director of marketing at WarehouseQuote.
Reporting by Richa Naidu and Arriana Mclymore in London; additional reporting by Trevor Hunnicutt; Editing by Lisa Jucca and Rod Nickel, Reuters
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Stocks Climb on Hopes of Easing US-China Trade Tensions
The S&P 500 Index ($SPX) (SPY) today is up +0.21%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.11%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.46%. June E-mini S&P futures (ESM25) are up +0.21%, and June E-mini Nasdaq futures (NQM25) are up +0.42%. Stock indexes recovered from early losses and are moving higher today, with the Nasdaq 100 reaching a 3 1/2-month high. Stocks are climbing on hopes that trade tensions will ease between the US and China after China's state media Xinhua News Agency reported that US President Trump and Chinese President Xi Jinping spoke by telephone today. President Xi agreed to more talks with Mr. Trump and urged the US to remove 'negative' measures that have roiled trade tensions between the two countries. The Chinese president also said the countries should work to reduce misunderstandings and that Trump was welcome to visit China. Stocks also garnered support from today's economic news that showed the US trade deficit in April shrank to a 20-month low, a positive factor for Q2 GDP. Stocks were under early pressure today on concerns about the US labor market after weekly jobless claims unexpectedly rose to a 7-3/4 month high. Also, today's downward revision to US Q1 nonfarm productivity and upward revision to Q1 unit labor costs were bearish for stocks. In addition, higher bond yields are negative for stocks as the 10-year T-note yield is up +3 bp to 4.39% as it rebounded from a 4-week low of 4.31% on negative carryover from a slide in 10-year German bunds after ECB President Lagarde said the ECB was nearing the end to its rate cutting cycle. US weekly initial unemployment claims unexpectedly rose +8,000 to a 7-3/4 month high of 247,000, showing a weaker labor market than expectations of a decline to 235,000. The US Apr trade deficit shrank to a 20-month low of -$61.6 billion, narrower than expectations of -$66.0 billion. US Q1 nonfarm productivity was revised lower to -1.5% from -0.8%. Q1 unit labor costs were revised upward to 6.6% from the previously reported 5.7%. Comments Wednesday evening from Minneapolis Fed President Kashkari signal he favors keeping interest rates steady when he said, 'The economy is seeming like it's pretty resilient so far, and so for me right now is the time to get data, see how the tariff negotiations shake out before we reach any firm conclusions about the direction of interest rates.' The markets are discounting the chances at 1% for a -25 bp rate cut at the next FOMC meeting on June 17-18. The markets this week will focus on any fresh trade or tariff news. On Friday, May nonfarm payrolls are expected to climb +125,000, and the May unemployment rate is expected to remain unchanged at 4.2%. Finally, May average hourly earnings are expected to rise +0.3% m/m and +3.7% y/y. Overseas stock markets today are mixed. The Euro Stoxx 50 is up +0.02%. China's Shanghai Composite climbed to a 1-1/2 week high and closed up +0.23%. Japan's Nikkei Stock 225 closed down -0.51%. Interest Rates September 10-year T-notes (ZNU2 5) today are down -5 ticks. The 10-year T-note yield is up +3.0 bp to 4.385%. Sep T-notes today fell from a 4-week high, and the 10-year T-note yield rose from a 4-week low of 4.310% and is moving higher. T-notes gave up early gains today and turned lower as stocks rallied on hopes of easing US-Chian trade tensions after the Xinhua news agency reported that President Trump and President Xi Jinping spoke by telephone today. T-notes also have a negative carryover from a slide in 10-year German bunds on hawkish comments from ECB President Lagarde, who said the ECB is nearing the end of its rate-cutting cycle. In addition, T-notes fell after today's news that showed US Q1 nonfarm productivity was revised downward and Q1 unit labor costs were revised higher. T-notes today initially moved higher when weekly US jobless claims unexpectedly rose to a 7-3/4 month high, a sign of labor market weakness and a dovish factor for Fed policy. Also, an easing in inflation expectations is bullish for T-notes after the US 10-year breakeven inflation rate fell to a 3-week low today at 2.297%. European government bond yields today are moving higher. The 10-year German bund yield rebounded from a 4-week low of 2.476% and is up +5.8 bp to 2.587%. The 10-year UK gilt yield rebounded from a 3-1/2 week low of 4.554% and is up +2.1 bp to 4.628%. Eurozone Apr PPI fell -2.2% m/m and rose +0.7% y/y, weaker than expectations of -2.1% m/m and +1.1% y/y. German Apr factory orders unexpectedly rose +0.6% m/m, stronger than expectations of -1.5% m/m. The ECB, as expected, cut the deposit facility rate by -25 bp to 2.00% from 2.25% and said, 'Inflation is currently at around the Governing Council's 2% medium-term target.' ECB President Lagarde said risks to growth 'tilted to the downside' as recent survey data points to weaker near-term prospects for the Eurozone economy. However, a stronger labor market and rising incomes will help the economy, and she wouldn't exclude further upward revisions to growth. She added that the ECB is getting toward the end of its rate cut cycle with today's rate cut. Swaps are discounting the chances at 42% for a -25 bp rate cut by the ECB at the July 24 policy meeting. US Stock Movers The strength of chip makers is supportive of the broader market. Micron Technology (MU) is up more than +4% to lead gainers in the Nasdaq 100. Also, ARM Holdings NV (ARM), Texas Instruments (TXN), ASML Holding NV (ASML), Applied Materials (AMAT), and Microchip Technology (MCHP) are up more than +1%. In addition, Lam Research (LRCX) and Analog Devices (ADI) are up more than +0.90%. Mining stocks are climbing today as the price of gold rose to a 4-week high and silver prices soared to a 13-year high. As a result, Freeport-McMoRan (FCX) is up more than +4%, and Anglogold Ashanti Plc (AU) is up more than +1%. MongoDB (MDB) is up more than +15% after reporting Q1 adjusted EPS of $1.06, well above the consensus of 67 cents, and raising its 2026 adjusted EPS forecast to $2.94-$3.12 from a previous estimate of $2.44-$2.62, stronger than the consensus of $2.60. Five Below (FIVE) is up more than +7% after reporting Q1 comparable sales rose +7.1%, better than the consensus of +6.37%, and forecast 2026 comparable sales will climb +3% to +5%, the midpoint above the consensus of +3.78%. Dollar Tree (DLTR) is up more than +7% to lead gainers in the S&P 500 after JPMorgan Chase upgraded the stock to overweight from neutral with a price target of $111. Verint Systems (VRNT) is up more than +6% after reporting Q1 adjusted EPS of 29 cents, better than the consensus of 19 cents. Brown-Forman (BF.B) is down more than -17% to lead losers in the S&P 500 after reporting Q4 net sales of $894 million, well below the consensus of $968.4 million. PVH Corp (PVH) is down more than -17% after cutting its 2026 adjusted EPS forecast to $10.75-$1.00 from a previous forecast of $12.40-$12.75, well below the consensus of $12.46. Ciena Corp (CIEN) is down more than -11% after reporting Q2 adjusted EPS of 42 cents, weaker than the consensus of 52 cents. Tesla (TSLA) is down more than -3% to lead losers in the Nasdaq 100, adding to Wednesday's -4% slide, after reporting its May vehicle shipments from China fell -15% y/y to 61,662 units, the eighth straight monthly decline. Costco Wholesale (COST) is down more than -2% after reporting May total comparable sales rose +4.3%, weaker than the consensus of +4.7% Procter & Gamble (PG) is down more than -1% to lead losers in the Dow Jones Industrials after announcing it expects to take a $1.6 billion charge over the next two years as it cuts its workforce by 7,000 or 15%. Earnings Reports (6/5/2025) Broadcom Inc (AVGO), Brown-Forman Corp (BF/B), Ciena Corp (CIEN), Docusign Inc (DOCU), Lululemon Athletica Inc (LULU), Toro Co/The (TTC), Vail Resorts Inc (MTN).
Globe and Mail
2 hours ago
- Globe and Mail
Broadcom Slides on Solid Earnings, AI Outlook Still Strong
[content-module:CompanyOverview|NASDAQ:AVGO] Given Broadcom's (NASDAQ: AVGO) explosive up moves after its past two earnings releases, many investors were likely hopeful to see fireworks again on June 5. The chip giant's price action would disappoint, but it should not discourage investors. Broadcom's fiscal Q2 earnings were solid by all accounts. Additionally, management provided some helpful commentary, despite deflecting some of the analysts' most pressing questions. Broadcom's Financials and Guidance Were Right on the Money Both on the top and bottom lines, Broadcom's fiscal Q2 2025 results came in almost exactly in line with expectations. The company's revenues of $15 billion resulted in growth of above 20%. This barely beat growth expectations of just under 20%. The company's adjusted earnings per share of $1.58 beat expectations of $1.57. The figure resulted in an earnings growth rate of under 44%, surpassing estimates of just under 43% growth. In terms of guidance, the company forecasted revenue of approximately $15.8 billion for fiscal Q3. This implies a growth rate of 21%, a sprinkle above estimates. Broadcom also predicted its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin to come in at 'at least' 66%. This implies a small contraction from the 67% figure it achieved in fiscal Q2. Tan's Takes: Business Remains Booming, but No Seismic Updates Revealed Chief Executive Officer (CEO) Hock Tan said the company's three hyper-scale customers and four potential ones are 'unwavering' in their AI investment plans. This is true even with the current macroeconomic challenges. The company backed this up by providing AI semiconductor guidance of $5.1 billion in fiscal Q3, which would be an increase of 60%. Additionally, the company confirmed that, based on current visibility, it expects this growth rate to continue through fiscal 2025 and fiscal 2026. This is a particularly positive sign, indicating that demand is not expected to slow down anytime soon. However, to the chagrin of analysts, Tan firmly refused to give insights on when revenue contributions for its prospective customers might come. Tan said the company would likely not provide updates on this until sometime in fiscal 2026. He also refused to provide any type of updates to the company's serviceable addressable market (SAM) estimates. Tan provided notable news on the company's infrastructure software segment, particularly when it came to moving VMware customers from perpetual licenses to subscriptions. This has been key to the company's software success. Shifting customers to subscriptions boosts recurring revenue. It also upsells them to a more comprehensive package. Now, 87% of the company's 10,000 largest VMware customers have transitioned to the subscription model, a significant increase from just 70% a quarter ago. Tan added that two-thirds of the overall customer base have transitioned, moderately up from 60% last quarter. Another interesting highlight was the company's AI networking revenue. This came in strong at 40% of total AI revenue, the same as the prior quarter. The company expected this figure to drop closer to 30%, but it hasn't. The company continues to guide that, on average, AI networking will make up around 30% of total AI revenue over time. Tan said the company was experiencing a positive surprise in AI networking. He said that 'scale-up' data center server architectures are increasingly adopting Ethernet. Scale-up refers to when server racks pack compute chips more densely. Meanwhile, "scale-out" architectures increase computing capacity by adding more server racks across a data center. Scale-up architecture requires 5 to 10 times higher switch density than scale-out architectures. This creates a significant need for the company's new high-capacity Tomahawk 6 switch chips, which offer leading-edge port density and bandwidth. Broadcom Shares Fall Moderately, But Remain Barely Off All-Time Highs [content-module:Forecast|NASDAQ:AVGO] By the end of after-hours trading, shares were down around 4%. Broadcom's share drop shows mild disappointment in its financials. It is also indicative of the fact that there was no groundbreaking news in the call. Still, it's hard to be overly disappointed. The stock was trading very close to an all-time high before the result. At the conclusion of after-hours trading, shares were down less than 5% from their all-time closing high. The market will want to see much larger beats to send shares soaring, as in past quarters. Getting more information around contributions from prospective AI-chip customers could also do the trick. Potential analyst upgrades may also propel shares higher as information from these earnings gets digested further. Overall, things at Broadcom are going according to plan. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
Globe and Mail
5 hours ago
- Globe and Mail
Frost & Sullivan: iRegene Therapeutics Honored as "2025 Forbes China Leading Enterprises in Industry Development"
Shanghai, China--(Newsfile Corp. - June 8, 2025) - Recently, The "2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor," jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund. Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies. iRegene Therapeutics Honored as 2025 Forbes China Leading Enterprises in Industry Development Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala. AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases. iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the "AI+Chem" platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies. With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial. In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, bringing strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy. To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene - Danaher Joint Innovation Center, which is the world's first "Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems". The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research. iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression. About iRegene Therapeutics iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine - making advanced therapies accessible to patients worldwide. In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024.
